Investigational Cancer Therapeutics Fellowship

The Investigational Cancer Therapeutics (ICT) Fellowship provides an exemplary training experience for fellows who wish to become experts in personalized cancer therapies, early phase clinical trials and drug development. We prepare fellows for careers as the next generation of independent clinical researchers.

The fellowship offers a one- or two-year experience. Fellows are trained in developing and conducting innovative clinical/translational trials with novel agents and are prepared for careers in academics, the pharmaceutical industry or government.    

UT MD Anderson provides a rich experience for fellows. Over 171,423 patients, including 43,000 new patients, were seen in Fiscal Year 2024. Additionally, over 8,000 participants were enrolled in more than 1,000 clinical trials exploring innovative treatments. Our department alone oversaw 212 actively enrolling therapeutic trials and enrolled 1,090 patients on our protocols. Nearly half of our active Phase I trials are first-in-human studies.

There is a wealth of opportunity for interactions with a wide variety of investigators who are internationally known for their expertise in basic, translational and/or clinical science. Fellows will learn how to write trials, interact with sponsors, develop translational endpoints to understand drug impact and factors predicting response and host toxicity, present data at national or international meetings, analyze data and write/complete manuscripts.